ArticleGynecologic oncology reports2025
Development of immune radiotherapy with yttrium by targeting Frizzled homologue 10 (FZD10) in cervical cancer.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological modulation of stem cells signaling pathway for therapeutic applications.Stem cell research & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Radioimmunotherapy (RIT) is a combination of the therapeutic properties of radioisotopes and specific antibodies used to eliminate tumors. Methods: The expression of FZD10 was evaluated via immunohistochemistry using formalin-fixed paraffin blocks collected from 84 patients with cervical cancer who underwent surgery. Normal cervical from 10 patients, normal ovarian tissues from 10, uterine carcinomas from 10, and uterine sarcomas from 9 were used for comparison.Mice inoculated with the SiHa cell line, which is derived from cervical squamous cell carcinoma, were used to examine the effects of Results: The evaluation results indicated that 70 (91 %) of the cervical cancer cases expressed FZD10 more frequently than 3 (30 %), 1 (10 %), 2 (20 %), and 0 (0 %) of the normal cervix, normal ovary, uterine carcinoma, and uterine sarcoma cases, respectively. The group treated with 3.7 MBq of Conclusions: FZD10 may be an appropriate target and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.